The Design and Results of the FIRE-3 Trial
Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.
Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.
In the randomized phase III FIRE-3 clinical trial, cetuximab (Erbitux) plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) was compared to bevacizumab (Avastin) plus FOLFIRI for first-line treatment of metastatic colorectal cancer and KRAS wild-type tumors.
Clinical Pearls I
In the intent-to-treat population, there was no significant difference observed with regard to objective response rate. Heinemann notes that cetuximab showed benefit in assessable patients. Further, the median time to progression-free survival was nearly the same in the two arms (10.0 vs 10.3 months respectively). Overall survival was markedly longer in the cetuximab arm (28.7 months) compared to the bevacizumab arm (25.0 months).
- The FIRE-3 trial was a randomized phase III trial
- The trial analyzed FOLFIRI + cetuximab versus FOLFIRI + bevacizumab for metastatic colorectal cancer
Clinical Pearls II
- In the intent-to-treat population, there was no significant difference with regard to objective response rate
- Cetuximab showed benefit among all assessable patients
<<<
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
